The 28 analysts covering Sarepta Therapeutics(SRPT) have given a “Buy” rating on average on the company’s stocks. One analyst issued a rating of “sell” on the company’s stocks, three analysts have issued a rating of “hold” on the company’s stocks,21 analysts have issued a rating of “buy” on the company’s stocks, and one analyst has issued a rating of “strong-buy” on the company’s stocks. The target price on average for 12 months among brokers is $196.08 in the past year.
Many research reports have been submitted on SRPT. Berenberg Bank issued a rating of “Hold” and a price target of $140.00. Citigroup Inc. raised the target price of the company’s stocks from $190.00 – $215.00 on Monday. HC Wainwright decreased the price target of the company’s stocks from $260.00 – $221.00 and issued a rating of “buy” on the company’s stock on August 31st, Monday. SVB Leerink decreased the target price of the company’s stocks from $214.00 – $197.00 and issued a rating of “outperform” on the company’s stocks on November 6th, Friday. Bank of America lowered the price target of the company’s stocks from $190.00 – $189.00 and issued a rating of “buy” on the company’s stocks on August 21st, Friday.
More About The SRPT Stock
SRPT’s stock trading increased by $1.74 on Friday, hitting $172.80.The company has $78.06 as its 12 months low and $178.66 as its 12 months high. The company has $143.87 as its moving average for 50 days and $149.43 as its moving average for 200 days. It has a 0.67 ratio between the debt and equity,6.42 quick ratio, and 6.93 current ratios. The company has $13.64 billion in market capitalization, a -24.37 P/E ratio, and a 1.82 beta.
The company focuses on the development and discovery of RNA therapeutics, genetic modalities, and gene therapy approaches for treating rare diseases. The company provides EXONDYS 51 and VYONDYS 53 injections to treat DMD.
